Efavirenz

Efavirenz does not announce itself as a psychoactive experience in any conventional sense. It arrives instead as a quiet disturbance in the architecture of sleep and waking. In the first days and weeks of treatment, the most common experience is a strange vivification of the hypnagogic state, that liminal territory between wakefulness and sleep. As you lie in bed, the darkness behind closed eyelids begins to populate itself with unusually vivid imagery. Colors bloom and shift. Faces may appear with uncanny detail and then dissolve. The transition into sleep becomes a corridor of hallucinatory fragments that feel more substantial and persistent than ordinary pre-sleep imagery.

Dreams themselves become extraordinary in their vividness, complexity, and emotional intensity. They are often described as cinematic, as though the sleeping mind has gained access to a more powerful rendering engine. Nightmares are common, and they carry a visceral, embodied quality that can linger well into the morning. Some users report lucid dreaming, where awareness of the dream state coexists with the dreaming itself. Upon waking, there may be a period of confusion in which the dream reality and waking reality seem equally plausible, and the boundary between the two takes several minutes to reassert itself.

During waking hours, the effects are subtler but still perceptible. There is a mild dizziness or lightheadedness that ebbs and flows without clear pattern. Concentration may feel slightly impaired, as though a thin gauze has been drawn between the mind and its objects of focus. Some users describe a gentle derealization, a sense that the world looks faintly artificial or staged, like a set in a play about ordinary life. Colors may appear marginally more vivid, and there is occasionally a barely perceptible wavering at the edges of the visual field. These effects are mild enough that many users learn to ignore them, but they contribute to an overall sense that baseline consciousness has been subtly but persistently altered.

These neuropsychiatric effects typically diminish over the first two to four weeks of treatment as the body adjusts, though some users report that the vivid dreams persist indefinitely. The experience is not sought out recreationally and is generally regarded as a tolerable side effect rather than a desired state. Nonetheless, for those who pass through it, efavirenz offers a curious window into how pharmacological tinkering with neural circuitry can produce perceptual changes that, while modest in scale, are genuinely strange.

Pharmacodynamics Anti-HIV effects Efavirenz falls in the NNRTI class of antiretrovirals. Both nucleoside and non-nucleoside RTIs inhibit the same target, the reverse transcriptase enzyme, an essential viral enzyme which transcribes viral RNA into DNA. Unlike nucleoside RTIs, which bind at the enzyme's active site, NNRTIs act allosterically by binding to a distinct site away from the active site known as the NNRTI pocket.

Efavirenz is not effective against HIV-2, as the pocket of the HIV-2 reverse transcriptase has a different structure, which confers intrinsic resistance to the NNRTI class.

As most NNRTIs bind within the same pocket, viral strains which are resistant to efavirenz are usually also resistant to the other NNRTIs, nevirapine and delavirdine. The most common mutation observed after efavirenz treatment is K103N, which is also observed with other NNRTIs. Nucleoside reverse-transcriptase inhibitors (NRTIs) and efavirenz have different binding targets, so cross-resistance is unlikely; the same is true with regard to efavirenz and protease inhibitors.

Neuropsychiatric effects Efavirenz has been found to have affinity for a variety of targets to varying degrees and appears to act as an antagonist of the serotonin 5-HT2A (specifically Gq signaling), 5-HT2B, 5-HT2C, and 5-HT3 receptors, as an inverse agonist of the serotonin 5-HT6 receptor, as a dual GABAA receptor positive allosteric modulator and orthosteric site antagonist, as a serotonin–dopamine reuptake inhibitor (SDRI), as a vesicular monoamine transporter 2 (VMAT2) inhibitor, as a monoamine oxidase inhibitor (MAOI) of MAO-A, and as an antagonist of the muscarinic acetylcholine M1 and M3 receptors. Efavirenz produces the head-twitch response, a behavioral proxy of serotonergic psychedelic effects, in animals, and can partially substitute for LSD and MDMA in animal drug discrimination tests. Induction of the head-twitch response and substitution for LSD by efavirenz can be abolished by serotonin 5-HT2A receptor antagonists or serotonin 5-HT2A receptor knockout. Efavirenz does not substitute for cocaine or carisoprodol. The drug is not self-administered and does not produce conditioned place preference (CPP) in animals.

As of 2016 the mechanism of efavirenz's neuropsychiatric adverse effects was not clear. It appears to produce neurotoxicity, possibly by interfering with mitochondrial function, which may in turn possibly be caused by inhibiting creatine kinase but also possibly by disrupting mitochondrial membranes or by interfering with nitric oxide signalling. Some neuropsychiatric adverse effects may be mediated through cannabinoid receptors, or through activity at the serotonin 5-HT2A receptor, but efavirenz interacts with many central nervous system targets, so this is not clear. The neuropsychiatric adverse effects are dose-dependent. Although efavirenz appears to act as a serotonin 5-HT2A receptor antagonist, it has been suggested that it might exert functional selectivity and act as an agonist of the receptor for certain signaling pathways, which could in turn explain its hallucinogenic and LSD-like effects. However, this hypothesis remains to be evaluated. Conversely, research suggests that efavirenz may actually be a partial agonist of the serotonin 5-HT2A receptor. The effects of efavirenz in animals and humans are consistent with it being a serotonergic psychedelic.

Pharmacokinetics The onset of action of efavirenz is 3 to 5hours and its elimination half-life is 52 to 76hours with a single dose and 40 to 55hours with continuous administration. The shorter half-life with chronic administration may be due to induction of cytochrome P450 enzymes by efavirenz.

The history of Efavirenz is intertwined with the broader story of psychedelic research, which has oscillated between periods of intense scientific interest and strict prohibition.

Like many psychedelic compounds, Efavirenz was either synthesized in a laboratory setting or identified as a naturally occurring psychoactive substance through ethnobotanical research. The mid-20th century saw an explosion of interest in psychedelic compounds, with researchers exploring their potential applications in psychotherapy, creativity enhancement, and the study of consciousness.

The political and cultural backlash of the late 1960s and early 1970s led to the criminalization of most psychedelic substances, effectively halting legitimate research for decades. The resurgence of psychedelic research beginning in the 2000s — often called the "psychedelic renaissance" — has renewed scientific interest in this class of compounds, with clinical trials exploring applications in treatment-resistant depression, PTSD, end-of-life anxiety, and addiction.

Efavirenz exists within this broader pharmacological and cultural context, with its specific history shaped by its date of discovery, legal status, availability, and unique pharmacological profile.